McKinsey August 17, 2020
Alex Davidson, Chris Llewellyn, Dan Tinkoff, and Manola Vyaravanh

Life-sciences companies have yet to realize the full potential of digital and analytics. Pioneers are finding success by focusing on entire parts of the business system rather than use case projects.

Life-sciences companies are navigating unprecedented yet uncertain times. The collision of scientific progress, technology disruptions, and innovation in clinical practice has tremendous potential to improve patients’ lives and create corporate value. Yet it is not proving easy to realize that potential.

Most life-sciences executives agree that long-term value creation lies in innovation-led growth, with digital and analytics at its core. And most companies have made significant investments to harness that value, undertaking projects and pilots that give glimpses of the exciting rewards ahead for stakeholders. But the vision...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Analytics, Biotechnology, Digital Health, Pharma / Biotech, Technology
Related Articles:
Cullinan Nets $280M Investment and Targets CD19 in Lupus
Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too
Fierce Biotech Layoff Tracker 2024: Ultimovacs says goodbye to 40% of staff; Major pharmas turn to layoffs
Lilly's Prevail walks away from Precision gene editing collab
Eli Lilly's tirzepatide scores again, this time in 2 sleep apnea trials

Share This Article